Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for elderly lymphoma patients: a gentler treatment that preserves independence

NCT ID NCT04113226

Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on maintaining the patients' ability to perform daily activities independently. Participants receive either the lenalidomide combination or standard chemotherapy, with the goal of finding a treatment that balances effectiveness with quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rituximab and Lenalidomide
What this could lead to
If successful, this could offer a gentler, effective treatment option for elderly patients with relapsed DLBCL, helping them live longer while maintaining independence.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Lenalidomide can cause side effects like low blood counts, fatigue, or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

1 person

The number who actually took part.

Started

Nov 2021

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

75 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 75 years old * Histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including all clinical subtypes (primary mediastinal, intravascular, etc...), with all aaIPI. May also be included : transformed DLBCL from low grade lymphoma (Follicular, other...) and DLBCL associated with some small cell Infiltration in bone marrow or lymph node or CD20+ B-cell lymphoma, with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma or CD20+ Follicular lymphoma grade 3B or CD20+ Aggressive B-cell lymphoma unclassifiable * Relapse ≥ 6 months * ADL ≥ 2 * Negative HIV, HBV (anti-HBc negativity) and HCV serologies test within 4 weeks before inclusion * Patient able to give his consent and having signed a written informed consent * Registration in a national health-care system Exclusion Criteria: * Central nervous system or meningeal involvement by lymphoma * Poor renal function (creatinine clearance \< 30 ml/min, according to MDRD formula) * Poor hepatic function (total bilirubin level\>30mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma * Neuropathy grade \> 1 * Poor bone marrow reserve as defined by neutrophils\<1.5 G/l or platelets\<100 G/l, unless related to bone marrow infiltration * Other concomitant or previous malignancy, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for \<5 years * Other serious and uncontrolled non-malignant disease. * Insufficient proficiency of the French language and disability to complete a questionnaire * Patient under guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy Diffuse large B-cell lymphoma (DLBCL), nos Elderly

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.